The CPEB4 antibody is a research tool designed to detect and study the Cytoplasmic Polyadenylation Element-Binding Protein 4 (CPEB4), a member of the CPEB family of RNA-binding proteins. CPEB proteins regulate mRNA translation by binding to cytoplasmic polyadenylation elements (CPEs) in the 3' untranslated regions (UTRs) of target mRNAs, modulating their poly-A tail length and thus their stability and translational efficiency. CPEB4. in particular, has gained attention for its role in cellular stress responses, cancer biology, and neurodegenerative diseases. It is overexpressed in certain cancers, where it promotes tumor angiogenesis, metastasis, and chemoresistance by regulating pro-tumorigenic mRNAs. In neurodegenerative contexts, CPEB4 dysfunction has been linked to protein aggregation and synaptic defects.
CPEB4 antibodies are typically produced in hosts like rabbits or mice using immunogenic peptides derived from conserved regions of the human CPEB4 protein. These antibodies enable researchers to investigate CPEB4 expression, localization, and interactions via techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Validated antibodies are critical for distinguishing CPEB4 from other CPEB family members (e.g., CPEB1-3) due to structural similarities. Commercial CPEB4 antibodies often include validation data (e.g., knockout cell line controls) to ensure specificity. Their applications span basic research in gene regulation, cancer mechanisms, and neurological disorders, as well as potential diagnostic or therapeutic development.